Physician

Yusuf Haroon Ahmad, M.D.

According to 2025 Medicare claims, Yusuf Ahmad, M.D. (NPI: 1467421131) practices medical oncology in the Tucson, AZ market, with the plurality of this provider's patient population coming from Pima, AZ. This provider's primary affiliated billing organization is ARIZONA BLOOD AND CANCER SPECIALISTS, PLLC (NPI: 1093370918; TIN: 834425637) and primary practice location at 85737-7295.

Ahmad's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 352 traditional Medicare patients, billed 146,075 HCPCS/CPT codes, and received $1,914,769 in Medicare payments. The top billing code was 99204 (New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more). Part D data shows 892 prescription claims across 156 beneficiaries totaling $2,140,179 in drug costs, led by Revlimid (Lenalidomide). 2023 DME data shows 22 claims. Open Payments data shows 110 records totaling $2,885. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $1,341,855 and ending at $1,914,769. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $1,399,915 and ending at $2,140,179. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $5,643 to $1,217.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	330	70,917	$1,341,855
2016	320	66,890	$1,314,937
2017	334	79,892	$1,489,223
2018	344	116,207	$2,195,113
2019	478	114,497	$2,103,710
2020	310	105,298	$1,582,547
2021	544	122,596	$2,163,266
2022	766	164,324	$2,955,335
2023	464	135,533	$1,524,866
2024	352	146,075	$1,914,769

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	144	1,003	$1,399,915
2016	142	975	$1,995,972
2017	148	1,067	$2,562,439
2018	169	1,078	$2,306,970
2019	158	881	$2,075,412
2020	128	633	$1,132,140
2021	164	1,040	$2,773,236
2022	241	1,387	$5,977,310
2023	204	1,040	$2,580,974
2024	156	892	$2,140,179

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	65	$5,643
2016	N/R	30	$1,574
2017	N/R	12	$391
2018	N/R	26	$959
2019	N/R	24	$832
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	46	$1,941
2023	N/R	22	$4,229
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	82	82	$120
96413	Administration of chemotherapy into vein, 1 hour or less	45	209	$95
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	94	316	$95
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	227	510	$65
96367	Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less	47	241	$21

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	36	945	$648,005
Ibrance	Palbociclib	11	308	$165,258
Ninlaro	Ixazomib Citrate	13	364	$156,552
Venclexta	Venetoclax	18	538	$110,834
Calquence	Acalabrutinib Maleate	12	360	$81,549

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	110	$2,885	Janssen Biotech, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Yusuf Haroon Ahmad, M.D.?

Tedicare shows public-source Medicare data for Yusuf Haroon Ahmad, M.D. (NPI 1467421131), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Yusuf Haroon Ahmad, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Yusuf Haroon Ahmad, M.D.?

Yusuf Haroon Ahmad, M.D. is linked to ARIZONA BLOOD AND CANCER SPECIALISTS, PLLC (billing NPI 1093370918) in the available physician profile data.

Does Yusuf Haroon Ahmad, M.D. have Open Payments data?

Yusuf Haroon Ahmad, M.D. has 110 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.